MedPath

Phentolamine

Generic Name
Phentolamine
Brand Names
Oraverse
Drug Type
Small Molecule
Chemical Formula
C17H19N3O
CAS Number
50-60-2
Unique Ingredient Identifier
Z468598HBV
Background

Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine. It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis. Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.

Indication

1.用于预防和治疗嗜铬细胞瘤所致的高血压发作，包括手术切除时出现的阵发性高血压，也可根据血压对本品的反应用于协助诊断嗜铬细胞瘤；

2.治疗左心衰竭；

3.治疗去甲肾上腺素、去氧肾上腺素、间羟胺等静脉给药外溢，用于防止皮肤坏死；

4.临床还用于治疗男性勃起功能障碍（ED）。最新研究表明，本品与罂粟碱、前列地尔三联用药，可降低引起平滑肌收缩的交感神经张力，使阴茎动脉平滑肌松弛，增加阴茎动脉血流，有利勃起。

Associated Conditions
Mydriasis, Necrosis caused by norepinephrine extravasation, Pheochromocytoma, Sloughing Skin, Soft Tissue Anesthesia (Numbness), Hypertensive episodes
Clinical Trials
Related News

FDA Grants Fast Track Status to Opus Genetics' Eye Drop Treatment for Night Vision Impairment

• Opus Genetics receives FDA Fast Track designation for Phentolamine Ophthalmic Solution 0.75% to treat night driving impairment in post-keratorefractive surgery patients. • The company completes enrollment in VEGA-3 Phase 3 trial evaluating the same solution for presbyopia, with 545 participants across 39 U.S. sites. • LYNX-2 Phase 3 trial for post-surgical night vision impairment is 95% enrolled, with completion expected in first half of 2025.

Opus Genetics Advances LCA5 Gene Therapy Program with First Pediatric Patient Dosing and Promising Adult Data

• Opus Genetics has dosed the first pediatric patient in their Phase 1/2 trial of OPGx-LCA5 gene therapy for Leber congenital amaurosis, with initial data expected by Q3 2025. • New 12-month data from the first three adult patients treated with OPGx-LCA5 confirms durability of positive responses observed at 6 months, with results to be presented at a medical conference in Q2 2025. • The company has scheduled an FDA meeting in March 2025 to discuss Phase 3 trial design and registrational endpoints, marking a significant step toward potential therapeutic advancement.

Ashvattha Therapeutics' Migaldendranib Shows Promise in Reducing Treatment Burden for Wet AMD and DME

• Ashvattha Therapeutics announced positive Phase 2 data for Migaldendranib (MGB), a subcutaneous nanomedicine, in treating wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). • The study showed a significant reduction in the need for anti-VEGF intravitreal injections in patients treated with MGB, with a 69% and 76.5% reduction observed in wet AMD and DME, respectively. • MGB demonstrated maintenance of visual acuity and reduction of central subfield thickness, suggesting potential for convenient at-home treatment and reduced clinic visits for patients. • Ashvattha Therapeutics also secured $50 million in funding to advance the Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.

Endeavor BioMedicines' ENV-101 Shows Promise in Reversing Idiopathic Pulmonary Fibrosis in Phase II Trials

• Endeavor BioMedicines' ENV-101 targets the Hedgehog signaling pathway, aiming to reverse lung damage in IPF, unlike current treatments that only slow disease progression. • Phase IIa trials of ENV-101 demonstrated statistically significant improvements in lung function and structure, along with a favorable safety profile across 230 patients. • The ongoing Phase IIb WHISTLE-PF trial will assess lower doses of ENV-101 with standard-of-care therapies, with safety monitored by an independent review board. • Endeavor BioMedicines collaborates with patient advocacy groups to enhance trial participation and awareness, aiming for expedited access to ENV-101 for IPF patients.

Opus Genetics Gains FDA Agreement for Phase 3 Trial of APX3330 in Diabetic Retinopathy

• Opus Genetics has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for a Phase 3 trial of oral APX3330. • The Phase 3 trial will assess APX3330's efficacy in treating moderate to severe non-proliferative diabetic retinopathy (NPDR). • The primary endpoint is a reduction in 3-step or greater worsening on the binocular diabetic retinopathy severity scale (DRSS) score. • APX3330, a first-in-class Ref-1 inhibitor, aims to slow DR progression, with Opus seeking a partner to fund further development.

Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis

• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases

• Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases. • The acquisition expands the pipeline to include AAV-based gene therapies for IRDs and phentolamine ophthalmic solution for presbyopia, while seeking a partner for diabetic retinopathy program. • OPGx-LCA5, a gene therapy for LCA5, shows promising early Phase 1/2 data with visual improvements in patients, and pediatric enrollment is expected in early 2025. • The merger extends the company's cash runway into 2026, anticipating key clinical milestones, including data readouts from multiple Phase 1/2 and Phase 3 trials.

Phentolamine Ophthalmic Solution (Ryzumvi) Demonstrates Efficacy in Reversing Mydriasis in Phase 3 Trials

• Phentolamine ophthalmic solution 0.75% (Ryzumvi) significantly reversed pharmacologically-induced mydriasis in MIRA-2 and MIRA-3 Phase 3 trials. • A statistically significant percentage of subjects achieved mydriasis reversal at 90 minutes compared to placebo (p < 0.0001) in both trials. • The solution exhibited a favorable safety profile, with mild and transient adverse events, offering faster recovery from mydriasis. • Ryzumvi, already FDA-approved for mydriasis, is also being evaluated for presbyopia and dim light vision disturbances.

Ocuphire Pharma Initiates Phase 3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

• Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. • Phentolamine ophthalmic solution 0.75% is under development as a non-invasive alternative to traditional presbyopia treatments. • The VEGA-3 trial (NCT06542497) aims to assess the efficacy and safety of this novel ophthalmic solution.

Ocuphire Pharma Initiates Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

• Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. • The VEGA-3 trial is a randomized, double-masked, placebo-controlled study involving 545 participants, with top-line data expected in 2025. • Phentolamine ophthalmic solution 0.75% aims to provide a non-invasive alternative to traditional corrective measures for presbyopia. • Ocuphire anticipates using VEGA-3 data to support a supplemental New Drug Application with the FDA.

FDA Approves Ryzumvi for Treating Drug-Induced Mydriasis

The US FDA has approved Ryzumvi, a phentolamine ophthalmic solution, for the treatment of pharmacologically-induced mydriasis, offering a new option with fewer systemic side effects compared to current treatments.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy